Intellia Therapeutics, Inc.
(NASDAQ : NTLA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
2.77%201.021.2%$533.38m
GILDGilead Sciences, Inc.
3.81%75.550.9%$477.27m
BIIBBiogen Inc.
2.08%335.241.3%$392.66m
CELGCelgene Corporation
2.47%83.851.2%$347.55m
ILMNIllumina, Inc.
3.67%324.903.5%$308.56m
REGNRegeneron Pharmaceuticals, Inc.
5.29%397.522.6%$240.57m
ALXNAlexion Pharmaceuticals, Inc.
4.73%127.232.0%$225.24m
VRTXVertex Pharmaceuticals Incorporated
3.92%184.611.9%$218.73m
SRPTSarepta Therapeutics, Inc.
4.65%137.4516.4%$179.08m
AAgilent Technologies, Inc.
2.39%67.201.5%$161.25m
BMRNBioMarin Pharmaceutical Inc.
6.04%105.464.4%$143.55m
LGNDLigand Pharmaceuticals Incorporated
6.00%212.0823.3%$122.28m
VKTXViking Therapeutics, Inc.
5.95%15.050.9%$118.74m
NKTRNektar Therapeutics
2.51%50.315.6%$111.79m
EXASExact Sciences Corporation
2.30%67.2825.3%$105.38m

Company Profile

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.